Wei et al. concluded that PCA3 measurement can reduce the under-detection of high-grade disease in initial prostatic biopsies, while also minimising the over-detection of low-grade PC in repeat biopsies [215]. The gene discussed is PCA3; the disease is pachyonychia congenita.